ACTUATE THERAPEUTICS, INC.
ACTUATE THERAPEUTICS, INC. (ACTU): 5 pipeline candidates · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.9 months
D/E 1.35 · 0% dilution
Lead: Phase 2
5 candidates
N/A
0 buys · 1 sell (180d)
A transparent, data-derived signal for ACTUATE THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$49.0M
Cash
$8.1M
Quarterly Burn
$5.0M
Runway
4.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| 9-ing-41 | Phase 2 |
| elraglusib | Phase 1/Phase 2 |
| Elraglusib Injection | Phase 2 |
| Elraglusib Oral Tablet | Phase 2 |
| lomustine | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
60
Total value held
$34.4M
| Holder | Shares | Value |
|---|---|---|
| bios capital management, lp | 10,049,996 | $27.5M |
| vanguard capital management llc | 801,058 | $2.2M |
| blackrock, inc. | 427,153 | $1.2M |
| geode capital management, llc | 228,331 | $626K |
| connective capital management, llc | 113,266 | $310K |
| palogic value management, l.p. | 100,000 | $274K |
| northern trust corp | 97,851 | $268K |
| texas capital bank wealth management services inc | 94,592 | $259K |
| state street corp | 66,030 | $181K |
| vanguard fiduciary trust co | 62,592 | $172K |
Showing top 10 of 60 institutional holders of ACTUATE THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ACTUATE THERAPEUTICS, INC.'s pipeline?
ACTUATE THERAPEUTICS, INC. (ACTU) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ACTUATE THERAPEUTICS, INC.'s lead drug candidate?
ACTUATE THERAPEUTICS, INC.'s most advanced tracked candidate is 9-ing-41 (Phase 2) for Cancer.
What is ACTUATE THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ACTUATE THERAPEUTICS, INC. has approximately 4.9 months of cash runway.
What is ACTUATE THERAPEUTICS, INC.'s market capitalization?
ACTUATE THERAPEUTICS, INC.'s market capitalization is approximately $49.0M.
Who is the CEO of ACTUATE THERAPEUTICS, INC.?
Mr. Daniel M. Schmitt is the chief executive officer of ACTUATE THERAPEUTICS, INC. (ACTU).
Get the full picture on ACTUATE THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.